Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of COMBIVENT HFA vs CFC in Healthy Subjects
NCT02173678Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 1999
- Primary completion
- Nov 1999
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 1, randomised, double-blind trial of Combivent in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Potential bronchoconstriction, Forced expiratory volume in one second and 12 more. Started Oct 1999; status: completed.
02
Drugs
Combivent
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02173678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173678.